Hélène Moore appointed Head of Ethypharm Digital Therapy with responsibility for building a European Leader in this innovative field.

Saint-Cloud, France – May 6th, 2021 – One month after the acquisition of the exclusive rights for two innovative digital therapies in the Central Nervous System, deprexis® and vorvida®, Ethypharm announces the establishment of a new business unit, Ethypharm Digital Therapy SAS, and the appointment of Hélène Moore as Executive Vice-President (EVP) and Head of the entity.